Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?

The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?